As we witness steady progress towards the development of robust, scalable, and reproducible 3D tissue models for preclinical drug testing, there is a need for systematic physiological and pharmacological validation and benchmarking. Ongoing and future studies should generate evidence as to whether 3D tissue models are more predictive, help reduce the risk of failure rate, and can be used for decision making in the drug discovery and development pipeline. Here, we discuss the importance of harmonizing the validation of these models based on throughput capacity and physiological complexity as a requirement to establish their true translational capacity. We also outline our strategy for a novel 3D-tailored holistic drug discovery concept rather than piecemeal integration of 3D models into the current process.

随着我们见证在为临床前药物测试开发健壮，可扩展和可再现的3D组织模型方面取得的稳步进展，需要进行系统的生理和药理验证和基准测试。正在进行的和将来的研究应产生证据，证明3D组织模型是否更具预测性，有助于降低失败率的风险，并可以用于药物发现和开发流程中的决策。在这里，我们讨论根据吞吐能力和生理复杂性协调这些模型验证的重要性，以此作为建立其真实翻译能力的要求。我们还将概述针对新颖的3D定制的整体药物发现概念的策略，而不是将3D模型零碎集成到当前过程中的策略。